Last reviewed 2026-04-20 · How we verify

postoperative adjuvant chemotherapy

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Alopecia
• Fatigue
• Nausea
• Peripheral sensory neuropathy
• Mucositis oral
• Bone pain
• Diarrhea
• Anemia
• Myalgia
• Headache
• Arthralgia
• Neutrophil count decreased

Key clinical trials

• Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE) (PHASE2)
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (PHASE3)
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
• Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision (NA)
• TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (PHASE2)
• Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
• Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
• CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• postoperative adjuvant chemotherapy CI brief — competitive landscape report
• postoperative adjuvant chemotherapy updates RSS · CI watch RSS
• Peng Zhang portfolio CI